A 6-Year-Old With Becker Muscular Dystrophy and Catatonia.

PediatricsOct 1, 2026
Case ReportPediatricsPsychiatry

Stephanie A Lichtor, Mars Robinson, James Luccarelli et al.

✦ AI-curated · Sources linked

Case in brief

A 6-year-old boy presented with acute behavioral changes suggestive of catatonia, including altered speech and awareness. He was found to have previously undiagnosed Becker muscular dystrophy. Despite multiple medication trials and interventions, he showed no improvement until he received electroconvulsive therapy, resulting in significant recovery after a prolonged hospitalization.

Diagnostic / clinical pearl

Clinicians should consider catatonia in pediatric patients with acute behavioral changes, and a thorough medical evaluation is essential to identify underlying conditions.

Why it matters

This case underscores the need for timely access to electroconvulsive therapy in pediatric patients with severe catatonia, particularly when conventional treatments fail.

Source

PubMed · PMID 42705646

Published in Pediatrics. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.